398 - The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies [Poster abstract]
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: European Journal of Cancer, 69, Supplement 1, S. S131-
- Klassifikation
-
Medizin, Gesundheit
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2016
- Ereignis
-
Veröffentlichung
- (wo)
-
Amsterdam
- (wer)
-
Elsevier BV
- (wann)
-
2016
- Urheber
-
Lahdenranta, J.
Gerami-Moayed, N.
Burenkova, O.
Masson, K.
Raue, Andreas
Wainszelbaum, M.
MacBeath, G.
- DOI
-
10.1016/s0959-8049(16)32989-6
- URN
-
urn:nbn:de:bvb:384-opus4-1131986
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lahdenranta, J.
- Gerami-Moayed, N.
- Burenkova, O.
- Masson, K.
- Raue, Andreas
- Wainszelbaum, M.
- MacBeath, G.
- Universität Augsburg
- Elsevier BV
Entstanden
- 2016
Ähnliche Objekte (12)
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway
An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations
Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Fraktionierte lokoregionale Radioimmuntherapie mit 213Bi-anti-EGFR-MAk
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway
An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations
Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Fraktionierte lokoregionale Radioimmuntherapie mit 213Bi-anti-EGFR-MAk
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway
An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations
Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Fraktionierte lokoregionale Radioimmuntherapie mit 213Bi-anti-EGFR-MAk
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response